0001209191-24-000790.txt : 20240104 0001209191-24-000790.hdr.sgml : 20240104 20240104163010 ACCESSION NUMBER: 0001209191-24-000790 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240103 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Masoud Maher CENTRAL INDEX KEY: 0001874571 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 24512354 MAIL ADDRESS: STREET 1: C/O MAXCYTE, INC. STREET 2: 22 FIRSTFIELD ROAD, SUITE 110 CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-03 0 0001287098 MAXCYTE, INC. MXCT 0001874571 Masoud Maher C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 1 1 0 0 President and CEO 0 Employee Stock Option (right to buy) 4.42 2024-01-03 4 A 0 400000 0.00 A 2034-01-02 Common Stock 400000 400000 D This option grant was made pursuant to the terms of the letter agreement, dated as of December 11, 2023, by and between the Issuer and the reporting person, entered into in connection with his appointment as President and Chief Executive Officer of the Issuer, as set forth in a Current Report on Form 8-K filed by the Issuer on December 11, 2023. Of the shares underlying the option, 25% will vest on January 2, 2025 and the remaining 75% will vest in 36 equal monthly installments thereafter, in each case subject to the reporting person's continuous service with the Issuer at the applicable vesting date. /s/ Katie Kazem, Attorney-in-Fact 2024-01-04